Hughes-Wilson Alexandra 4

What Happened

• Alexandra Hughes‑Wilson, Chief Patient Access and Commercial Planning at Mereo BioPharma (MREO), received three equity award grants on February 1, 2026. The grants total 440,000 derivative securities (183,750 + 61,250 + 195,000) with an acquisition price of $0.00 (reported as award/grant, transaction code A). These are awards of company shares (derivative securities) rather than open‑market purchases or sales.

Key Details

• Transaction date: 2026-02-01; filing date: 2026-02-02 (timely filed).
• Awards: 183,750; 61,250; and 195,000 shares — total 440,000 shares; reported acquisition price $0.00 (derivative awards).
• Vesting notes from the filing:
  • F1: 25% vests on Feb 1, 2027; remainder vests in equal monthly installments over the following three years.
  • F3: Vests in substantially equal monthly installments over one year from the Feb 1, 2026 grant date.
  • F2: Each American Depositary Share (ADS) represents five ordinary shares (disclosure of ADS/ordinary share relationship).
• Shares owned after the transaction are not specified in the provided filing data.
• Filing code A indicates an award/grant (not a purchase or sale); no 10b5‑1 or tax‑withholding details were reported in the items provided.

Context

• These are newly granted, vested‑over‑time equity awards (derivatives). Because they vest in the future, they do not represent an immediate market trade or sale and are subject to the stated vesting schedules.
• Awards like these are common as compensation and retention tools; they differ from open‑market purchases (which some investors view as a stronger bullish signal).